Adaptive Biotechnologies (ADPT) Shares Outstanding (Weighted Average) (2018 - 2026)

Adaptive Biotechnologies has disclosed Shares Outstanding (Weighted Average) across 9 years of filings, most recently posting $155.5 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $155.5 million, up 4.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $155.5 million (up 4.24% YoY), and the FY2025 annual result was $151.7 million, up 3.14% from the prior year.
• Shares Outstanding (Weighted Average) came in at $155.5 million for Q1 2026 at Adaptive Biotechnologies, up from $151.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $155.5 million in Q1 2026 to a low of $141.7 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $145.8 million (2024), against an average of $146.6 million.
• Across the five-year window, Shares Outstanding (Weighted Average) rose 1.07% in 2022 and rose 4.24% in 2026, its largest moves.
• Adaptive Biotechnologies' Shares Outstanding (Weighted Average) stood at $142.5 million in 2022, then rose by 1.31% to $144.4 million in 2023, then gained by 1.88% to $147.1 million in 2024, then increased by 3.14% to $151.7 million in 2025, then increased by 2.5% to $155.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $155.5 million (Q1 2026), $151.7 million (Q4 2025), and $152.4 million (Q3 2025), per Business Quant data.